Key facts
- IsoBio’s last known valuation is $25.5M (Jul 2025).
- It has raised $5.0M across 1 recorded rounds; the latest was Seed Round ($1.7M) in Oct 2025.
- Notable investors include ASP Isotopes.
- IsoBio has filed 1 Form D with the SEC, most recently Nov 2025 ($1.7M sold to 2 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for IsoBio
Funding rounds
1 roundsAbout IsoBio
Developer of radiotherapeutic products designed for cancer treatment. The company's platform focuses on antibody-isotope conjugates that target both validated and novel tumor antigens, utilizing proprietary linker and conjugation methods, enabling patients in need of new cancer therapies to access potent anti-tumor activity with reduced off-target side effects.
- Sector
- Healthcare
- HQ
- Gladwyne, PA, United States
- Founded
- 2025
- Ownership
- Privately Held (backing)
IsoBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in IsoBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on IsoBio in its N-PORT filings yet. We sweep new filings monthly.